NHS Borders
Planning & Performance

NHS Borders
Education Centre
Borders General Hospital
Melrose
Roxburghshire
TD6 9BD
01896 825545
foi.enquiries@borders.scot.nhs.uk

Freedom of Information request 81-20

Request

1.

	Rheumatology	Dermatology	Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary?			

This data is available online at the following link - http://www.nhsborders.scot.nhs.uk/BordersFormulary/index.html - therefore under Section 25 of the FOI(S)A 2002 this data is accessible elsewhere.

2. Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the adalimumab therapy pathway*	Rheumatology	Dermatology	Gastroenterology
AMGEVITA first-line			
AMGEVITA second-line			
HUMIRA first-line			
HUMIRA second-line			
HYRIMOZ first-line			
IMRALDI first-line			

* How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

This data would only be held in a patient's medical record and to extract this information would require a manual trawl of all patient notes and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the FOI(S)A 2002, therefore we are not required to provide.

3. Please complete the table below:

Question	Department					
	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic arthritis	Rheumatoid arthritis	Ankylosing spondylitis	Crohn's disease	Ulcerative colitis
Are any local guidelines	**No**					

followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?	
Are there occasions where patients can receive adalimumab outside of NICE/SMC/AWMSG/National criteria?	**Any application to use Adalimumab 'off label'/outwith SMC criteria would be required to go through the NHS Borders non-formulary request or PACS 2 process.**

4. What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?

Contractual agreement	**Yes/No**
Block contracts	No
Fixed price on a patient-by-patient basis	No

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **81-20** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.